InflaRx stock rating cut, price target slashed to $2 by Raymond James

Raymond James downgraded InflaRx (IFRX) from Strong Buy to Outperform, significantly reducing the price target to $2.00 from $13.00, following the halted Phase 3 trial of vilobelimab for Pyoderma Gangrenosum due to futility. InflaRx will now focus on INF904 for Hidradenitis Suppurativa and Chronic Spontaneous Urticaria, with a Phase 2a readout upcoming; while Raymond James is positive on INF904's mechanism, the early stage of the program prompted the price target reduction, despite the company's cash runway extending into 2027.

Analysis

Raymond James has significantly altered its outlook on InflaRx NV (IFRX), downgrading the stock from Strong Buy to Outperform and slashing the price target from $13.00 to $2.00, reflecting a strongly negative sentiment. This revision directly follows the Independent Data Monitoring Committee's recommendation to halt the Phase 3 trial of vilobelimab for Pyoderma Gangrenosum (PG) due to a lack of observed treatment effect at the interim futility analysis, a development that precipitated a nearly 60% drop in IFRX's stock price over the past week, pushing it near its 52-week low of $0.71. In response, InflaRx has discontinued vilobelimab's PG development, redirecting focus and resources towards its INF904 program for Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU), with an upcoming Phase 2a readout now representing a critical inflection point for the company. While Raymond James expresses a positive view on INF904's mechanism, the early stage of these programs introduces significant uncertainty, justifying the reduced price target. Financially, InflaRx reports a cash runway extending into 2027, supported by approximately $84 million in reserves and a strong current ratio of 5.28, which should fund operations through the INF904 Phase 2a results; however, the company is noted to be rapidly burning through cash, though recent Q1 2025 R&D expenses of €8.0 million were below consensus and EPS of (€0.13) beat analysts' expectations. Despite the PG trial setback, vilobelimab has received European Commission marketing authorization for SARS-CoV2-induced septic acute respiratory distress syndrome. InvestingPro data suggests the stock may be undervalued at its current price, a sentiment somewhat echoed by Guggenheim Securities which maintained its Buy rating and $10 price target post-PG trial news, citing Inflarx’s substantial cash reserves and potential in immuno-dermatology, contrasting with Raymond James' more immediate caution driven by the clinical failure.

Key Decisions for Investors

• Investors should recognize the pivotal nature of the upcoming Phase 2a readout for INF904, as this will be the primary driver of future valuation following the vilobelimab PG trial failure.
• Monitor InflaRx's cash burn rate closely, despite the stated runway to 2027, and look for evidence of effective cost-saving measures as the PG clinical study concludes.
• Evaluate the current depressed share price and potential undervaluation against the significantly heightened risk profile and binary outcome associated with early-stage biotech development, particularly the success of INF904.